Patents by Inventor Bo Falck Hansen

Bo Falck Hansen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel Acylated Insulin Analogues and Uses Thereof
    Publication number: 20210094999
    Abstract: The present invention relates to novel insulin analogues and derivatives thereof, such as acylated insulin analogues, and their pharmaceutical use, in particular in the treatment or prevention of medical conditions relating to diabetes, obesity and cardiovascular diseases.
    Type: Application
    Filed: November 5, 2020
    Publication date: April 1, 2021
    Inventors: Grith Skytte Olsen, Bo Falck Hansen, Lauge Schaeffer, Ingrid Pettersson, Rita Slaaby, Jakob Brandt
  • Acylated insulin analogues and uses thereof
    Patent number: 10919949
    Abstract: The present invention relates to novel insulin analogues and derivatives thereof, such as acylated insulin analogues, and their pharmaceutical use, in particular in the treatment or prevention of medical conditions relating to diabetes, obesity and cardiovascular diseases.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: February 16, 2021
    Assignee: Novo Nordisk A/S
    Inventors: Grith Skytte Olsen, Bo Falck Hansen, Lauge Schaeffer, Ingrid Pettersson, Rita Slaaby, Jakob Brandt
  • Novel Acylated Insulin Analogues and Uses Thereof
    Publication number: 20190194285
    Abstract: The present invention relates to novel insulin analogues and derivatives thereof, such as acylated insulin analogues, and their pharmaceutical use, in particular in the treatment or prevention of medical conditions relating to diabetes, obesity and cardiovascular diseases.
    Type: Application
    Filed: August 16, 2018
    Publication date: June 27, 2019
    Inventors: Grith Skytte Olsen, Bo Falck Hansen, Lauge Schaeffer, Ingrid Pettersson, Rita Slaaby, Jakob Brandt
  • Novel 2,4-diaminothiazole derivatives
    Publication number: 20040210063
    Abstract: Novel 2,4-diaminothiazole derivatives of the general formula (I) which inhibit GSK-3 (glycogen synthase kinase-3), use of these compounds as medicaments, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful for the treatment of disorders, syndromes, diseases and conditions, wherein an inhibition of GSK-3 (glycogen synthase kinase-3) is beneficial, especially IGT (impaired glucose tolerance), type 1 diabetes, type 2 diabetes, obesity, Alzheimer's disease and bipolar disorder.
    Type: Application
    Filed: February 3, 2004
    Publication date: October 21, 2004
    Inventors: Andrew Neil Bowler, Bo Falck Hansen
  • Use of 2,4-diaminothiazole derivatives
    Publication number: 20010039275
    Abstract: 2,4-Diaminothiazole derivatives which inhibit GSK-3 (glycogen synthase kinase-3) and which are useful for the treatment and/or prevention disorders and diseases wherein an inhibition of GSK-3 is beneficial, especially especially Alzheimer's disease, bipolar disorder, IGT (impaired glucose tolerance), Type 1 diabetes, Type 2 diabetes and obesity.
    Type: Application
    Filed: January 31, 2001
    Publication date: November 8, 2001
    Inventors: Andrew Neil Bowler, Preben Houlberg Olesen, Anders Robert Sorensen, Bo Falck Hansen, Helle Worsaae, Peter Kurtzhals